GLMD - ガルメド・ファ―マシュ―ティカルズ (Galmed Pharmaceuticals Ltd.) ガルメド・ファ―マシュ―ティカルズ

 GLMDのチャート


 GLMDの企業情報

symbol GLMD
会社名 Galmed Pharmaceuticals Ltd. (ガルメド・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC) called aramchol. Its product candidate aramchol is a disease modifying treatment for fatty liver disorders including Non-Alcoholic Steato-hepatitis (NASH). The Company''s Aramchol is a conjugate of cholic acid and arachidic acid which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.   ガルメド・ファ―マシュ―ティカルズはイスラエルの臨床段階のバイオ医薬品会社。肝臓疾患やコレステロ―ル胆石のための一日一回経口療法の新治療薬の開発・商品化に従事。画期的医薬品(ファ―スト・イン・クラス)には、脂肪酸と胆汁酸を結合させた「aramchol」があり、非アルコ―ル脂肪性肝炎などの脂肪管疾患の応用治療となる製品候補を保有する。   Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
本社所在地 16 Tiomkin Street Tel Aviv 6578317 ISR
代表者氏名 Chaim Hurvitz チャイム・ハービッツ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +972 3-693-8448
設立年月日 41456
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 17人
url www.galmedpharma.com
nasdaq_url https://www.nasdaq.com/symbol/glmd
adr_tso
EBITDA EBITDA(百万ドル) -11.49600
終値(lastsale) 12.32
時価総額(marketcap) 257645129.28
時価総額 時価総額(百万ドル) 241.76590
売上高 売上高(百万ドル) 1.08500
企業価値(EV) 企業価値(EV)(百万ドル) 147.66090
当期純利益 当期純利益(百万ドル) -11.63600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Galmed Pharmaceuticals Ltd revenues remained flat at $538K. Net loss decreased 11% to $5.2M. Revenues reflect market conditions. Lower net loss reflects Research and development expenses decrease of 24% to $3.9M (expense) Financial expenses net increase of 29% to $143K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.48 to -$0.34.

 GLMDのテクニカル分析


 GLMDのニュース

   Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results  2019/11/06 12:00:00 PR Newswire
TEL AVIV, Israel, Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral SCD1 modulator currently in a Phase 3/4 clinical trial for the…
   Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6  2019/10/30 12:30:00 PR Newswire
TEL AVIV, Israel, Oct. 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial for the…
   The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout  2019/10/11 12:14:27 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) ( announced a deal to be bought by Belgium's UCB) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 10.) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Alkermes Plc (NASDAQ: ALKS ) Atreca Inc (NASDAQ: BCEL ) AzurRx BioPharma Inc (NASDAQ: AZRX ) (announced CEO departure) BioNano Genomics Inc (NASDAQ: BNGO ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) Cocrystal Pharma Inc (NASDAQ: COCP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Dermira Inc (NASDAQ: DERM ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genprex Inc (NASDAQ: GNPX ) Gossamer Bio Inc (NASDAQ: GOSS ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Homology Medicines Inc (NASDAQ: FIXX ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Jaguar Health Inc (NASDAQ: JAGX ) (announced plans to explore options to license Mytesi in China) Meridian Bioscience, Inc. (NASDAQ: VIVO ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) MOTIF BIO PLC/S ADR (: MTFB) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) Orgenesis Inc (NASDAQ: ORGS ) PAVmed Inc (NASDAQ: PAVM ) Precision BioSciences …
   The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO  2019/10/10 11:31:01 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: …
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   Key events next week - healthcare  2019-04-18
Noteworthy events during the week of April 21 - 27 for healthcare investors. More news on: Galmed Pharmaceuticals Ltd., Horizon Pharma plc, Concert Pharmaceuticals, Inc., Healthcare stocks news, , Read more …
   CNBC article highlights $35B market opportunity of NASH drugs  2018-12-31
CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ガルメド・ファ―マシュ―ティカルズ GLMD Galmed Pharmaceuticals Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)